Sinovac Biotech Ltd. reported a very strong first quarter, maintaining the successes that, across the board, China-based biopharmas have been able to announce for early 2008. In Sinovac’s case, Q1 revenues were more than twice those of the year-earlier quarter. The company said it generated $8.9 million in sales, an increase of 123%. Net income was up 106% at $1.6 million, or 4 cents per share, fully diluted.  The company said that its revenue increases were driven by Healive®, Sinovac’s Hepatitis A vaccine and its lead product. More details...

Stock Symbol: (AMEX: SVA)